BioNexus Gene Lab Corp. (BGLC) Earnings History
Annual and quarterly earnings data from 2016 to 2024
Loading earnings history...
BGLC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BGLC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 13.6% | -16.5% | -16.8% |
| 2023 | 13.6% | -26.5% | -26.9% |
| 2022 | 11.5% | -2.7% | -3.3% |
| 2021 | 16.4% | 7.9% | 5.6% |
| 2020 | 15.1% | 11.2% | 9.6% |
Download Data
Export BGLC earnings history in CSV or JSON format
Free sign-in required to download data
BioNexus Gene Lab Corp. (BGLC) Earnings Overview
As of May 9, 2026, BioNexus Gene Lab Corp. (BGLC) reported trailing twelve-month net income of -$2M, reflecting +41.2% year-over-year growth. The company earned $-1.28 per diluted share over the past four quarters, with a net profit margin of -16.8%.
Looking at the long-term picture, BGLC's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2020.
BioNexus Gene Lab Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including QDEL (-$1.21B net income, -41.5% margin), CLOV (-$57M net income, -4.4% margin), RNAZ (-$27M net income), BGLC has outperformed on profitability metrics. Compare BGLC vs QDEL →
BGLC Earnings vs Peers
Earnings metrics vs comparable public companies
BGLC Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$2M | +39.2% | -$2M | $-0.90 | -16.8% | -16.5% |
| 2023 | -$3M | -638.6% | -$3M | $-1.53 | -26.9% | -26.5% |
| 2022 | $-355,966 | -147.4% | $-291,177 | $-0.25 | -3.3% | -2.7% |
| 2021 | $751,571 | -31.3% | $1M | $0.53 | 5.6% | 7.9% |
| 2020 | $1M | +543.9% | $1M | $1.28 | 9.6% | 11.2% |
| 2019 | $-246,469 | -1031.7% | $-275,705 | $-0.03 | -194.1% | -217.2% |
| 2018 | $26,454 | +121.4% | $59,901 | $0.00 | 12.5% | 28.2% |
| 2017 | $-123,750 | -14720.4% | $-127,910 | $-0.02 | -114.9% | -118.8% |
| 2016 | $-835 | - | $-840 | $-0.00 | - | - |
See BGLC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BGLC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BGLC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
Is BGLC growing earnings?
BGLC EPS is $-1.28, with earnings growth accelerating to +41.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-2M.
What are BGLC's profit margins?
BioNexus Gene Lab Corp. net margin is -16.8%, with operating margin at -16.5%. Below-average margins reflect competitive or cost pressures.
How consistent are BGLC's earnings?
BGLC earnings data spans 2016-2024. The accelerating earnings trend is +41.2% YoY. Historical data enables comparison across business cycles.